Navigation Links
Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
Date:10/8/2008

Findings Confirm Potency of Poly-ICR as Vaccine Adjuvant

SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today presented positive data from preclinical studies using its proprietary Toll-like Receptor 3 agonist, Poly IC-Poly Arginine (Poly-ICR), at the World Vaccine Congress 2008 in Lyon, France. Study results demonstrated Poly-ICR to be a potent vaccine adjuvant targeting the Toll-like Receptor 3 (TLR3) pathway. Data showed that Poly-ICR, in combination with model antigens, elicits strong anti-target antibody and CD8 T-cell immune responses. These findings demonstrate the versatility of Poly-ICR, suggesting that the compound may possess broad potential for use in both therapeutic and prophylactic vaccines.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

Additional study findings presented today by Peter Emtage, Ph.D., Nventa's vice president of research and development, include:

-- Poly-ICR is stable and resistant to degradation by RNAses in

human serum;

-- Poly-ICR induces significant cytokine and chemokine production;

-- Poly-ICR matures dendritic cells, known as "the teachers of the

immune system".

In addition to incorporating Poly-ICR into future internal product candidates, Nventa is pursuing the development of Poly-ICR for topical application for the treatment of genital warts (GW) and actinic keratosis, a premalignant condition of the skin.

The company is also currently providing access to Poly-ICR to multiple leading vaccine developers in the U.S. and abroad, who are evaluating Poly-ICR for potential use into a wide range of vaccine products.

"These findings have confirmed the potency of Poly-ICR and highlighted the broad applicability of this compound for potential use in therapeutic and prophylactic vaccines," said
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nventa Develops Proprietary Vaccine Adjuvant
2. Nventa to Present at Bio 2008 International Convention
3. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
6. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
7. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
8. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
9. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
10. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
11. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 /PRNewswire/ ... the appointments of Dr. Ashraf Hanna , M.D., ... to its Board of Directors. Dr. Hanna is the ... Genentech and Chief Financial Officer for the Genentech Foundation, ... and Global Head of Business Development and Licensing for ...
(Date:9/18/2014)... , Sept. 18, 2014  Spring Bank ... therapeutics for the treatment of RNA viruses, today ... of Health (NIH) for animal testing of the ... pathogens, classified as "Special Pathogens," against which currently ... derived from Spring Bank,s proprietary Small ...
(Date:9/18/2014)... , Sept. 18, 2014   Auxilium Pharmaceuticals, ... specialty biopharmaceutical company, today announced the first presentation ... AUX-CC-867 MULTICORD (MULtiple Treatment Investigation of Collagenase Optimizing ... study evaluated collagenase clostridium histolyticum (CCH) for the ... same hand. In addition, the study examined expanded ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 6Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 7
... , , ... Incorporated, (IDEV) an emerging leader in the development and marketing ... patient was enrolled in the Company,s FDA-approved multi-center clinical trial ... for the treatment of biliary and peripheral artery disease (PAD) ...
... RYE, N.Y., Aug. 24 Curemark Founder and CEO Dr. ... International Epigenomics, Sequencing 2009 Conference at Harvard Medical School on ... to address this cutting-edge conclave is particularly significant, since epigenetics ... occur without a change in the DNA sequence. Presenters at ...
Cached Medicine Technology:IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent 2Curemark CEO Presents at Epigenomics Conference 2
(Date:9/18/2014)... 18, 2014 With the swift industrial ... products such as smart phones, tablets and PDAs, a ... way mobile devices are viewed these days. From only ... to becoming a mode for creating and delivering content ... long way. , The complete makeover of ...
(Date:9/18/2014)... County, NY (PRWEB) September 18, 2014 ... Westchester residents, community advocates, and volunteers supported United ... annual “Best Chefs and Fine Wines” event Monday, Sept. ... United Way’s health initiatives in Westchester and Putnam, such ... obesity, and steering teens away from risky behaviors like ...
(Date:9/18/2014)... molecules show promise in slowing the progression of ... linked to asbestos. Scientists from Case Western Reserve ... that application of curcumin, a derivative of the ... a protein inhibitor known to combat the progression ... Aug. 14 online edition Clinical Cancer Research ...
(Date:9/18/2014)... October is more than just the season ... the Centers for Disease Control’s National Intimate Partner and ... to the CDC survey, over a third of women ... experience some form of physical abuse, sexual assault, and/or ... that about half of both women and men experience ...
(Date:9/18/2014)... With the arrival of subsequent-entry biologics (SEBs) set to alter ... to educate stakeholders on their potential impact. The bottom line: ... patients must be well informed when speaking to their healthcare ... an infographic and an expert video explaining the impact of ... Arthritis Society’s position paper on SEBs. ,“This new ...
Breaking Medicine News(10 mins):Health News:Transparency Market Research: M-health Market Study 2018 2Health News:Transparency Market Research: M-health Market Study 2018 3Health News:Transparency Market Research: M-health Market Study 2018 4Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 2Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 3Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 2Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 3Health News:What you should know about domestic violence 2Health News:What you should know about domestic violence 3Health News:What you should know about domestic violence 4Health News:What you should know about domestic violence 5Health News:Subsequent-entry biologics set to alter the arthritis treatment landscape 2
... services company standardizes on AVG Network Edition , ... ... Pyramid Healthcare, founded in 1999, provides behavioral healthcare services for ... and behavioral problems. The company has 23 locations across Pennsylvania, ...
... (CTI) (Nasdaq and MTA: CTIC) announced today that they ... with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) ... the initial $7.5 million payment in connection with the ... up to an additional $15 million in product sales ...
... Immucor, Inc.,(Nasdaq: BLUD ), a global leader ... reported financial results,for the fiscal second quarter ended November 30, ... -- Revenue for the fiscal second quarter ... the same period last year. , ...
... of America,Inc. announced the formation of ROSA of ... ROSA of South Alabama is a joint ... P.C., Monroeville Radiation -,Oncology, P.C., and South Alabama ... of America, Inc. ROSA of South,Alabama will ...
... The following is a statement by Lois Aronstein, ... State address put forth recommendations on a number of ... financial security of New Yorkers of all ages.AARP commends ... Plus Program to 200 percent of the federal poverty ...
... also bolsters tie between vitamin D and the brain ... have identified nine genes that might make people more ... confirmed earlier reports that a variation in the vitamin ... risk for Alzheimer,s. Low levels of vitamin D ...
Cached Medicine News:Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 2Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 3Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 4Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 3Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 4Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 2Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 3Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 4Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 5Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 6Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 7Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 8Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 9Health News:Ambulatory Services of America, Inc. Announces Joint Venture with Gulf Coast Cancer Centers 2Health News:9 Genes Are Linked to Alzheimer's 2
... Ad-Techs Foramen Ovale Electrodes provide you ... These electrodes offer the same proven design ... that they are placed using an introducing ... a smaller electrode body diameter, 3 to ...
... The Small Joint Ball Electrode ... in small joint applications. With its ... tip, controlled capsuloligamentous or tendinous tissue ... When used in conjunction with the ...
... is designed to replace the carpal scaphoid bone. ... pole which fits under a shelf formed in ... suture hole on the proximal hole for suture ... the early postoperative period until a firm capsuloligamentous ...
... two-piece Titanium (Ti-6Al-4V) screw offered in two ... of lengths. The two pieces are loaded ... A single instrument set contains all items ... Standard and Mini Kompressor Compression Screws. , ...
Medicine Products: